Healthcare / Drug Manufacturers - Specialty & GenericCanadian Sec
$0.13
-0.02 (-10.34%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-5.0M · quality 45.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
14/100
F
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$17M
P/E
N/A
•EV/EBITDA
30.6x
↑ROE
-20.5%
↓Gross Margin
18.8%
↓Debt/Equity
1.57
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+65.2%
FCF CAGR
—
FCF margin
18.0%
FCF / Net income
-0.78x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $8.9M · net income $-2.1M · FCF $1.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $8.9M | $8.9M | $5.2M | $5.6M | $2.0M |
| Net Income | $-2.1M | $-2.1M | $-4.7M | $-2.6M | $-2.9M |
| EBITDA | $972527.00 | $972527.00 | $-2.1M | $-576336.00 | $-1.4M |
| EPS | -0.02 | -0.02 | -0.04 | -0.02 | -0.02 |
| Gross Margin | 18.8% | 18.8% | -6.4% | 13.2% | 42.5% |
| Operating Margin | -10.3% | -10.3% | -69.5% | -36.5% | -72.8% |
| Net Margin | -23.0% | -23.0% | -90.3% | -46.3% | -147.3% |
| Balance Sheet | |||||
| Debt/Equity | 1.57 | 1.57 | 1.34 | 0.93 | 0.99 |
| Current Ratio | 0.59 | 0.59 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.6M | $1.6M | $-5.0M | $-5.2M | $-4.1M |
| Returns | |||||
| ROE | -20.5% | -20.5% | -39.6% | -17.4% | -17.3% |
| Valuation | |||||
| EV/EBITDA | 30.59 | 30.59 | — | — | — |
| P/B | 1.70 | 1.70 | 3.64 | 2.15 | 9.63 |
| Growth & Yield | |||||
| Revenue Growth | 71.1% | 71.1% | -7.0% | 183.3% | — |
| EPS Growth | 50.0% | 50.0% | -100.0% | 0.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-35.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.04 → -0.02
Residual
-35.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.